up for 10 years after therapy, more than half a million women in Germany are currently being treated and/or followed up. In addition, an estimated 60 000 women have metastatic disease. To put these figures into context, in 2010 32 033 000 adult women were living in Germany [6]in other words, one in every 55 women is receiving oncologic care or follow-up for breast cancer. These figures make it obvious that the care of patients with breast cancer has an enormous health economic impactboth in an adjuvant and a palliative setting.
Overview of the Health Economic Aspects of Individualised Therapy Options ! New molecular and genetic tests are becoming increasingly central in research and clinical practice. Using these tests to offer individualised treatment to patients with breast cancer is particularly important for health economics as the targeted use of therapy based on these tests can increase the effectiveness of treatment and reduce follow-up costs by preventing the recurrence and metastatic disease. Reducing over-treatment additionally saves financial resources, both directly and indirectly. Preventable direct costs include the costs of systemic therapies and supportive treatments. Preventable indirect costs include the cost of travel to clinics and medical practices, waiting times and reduced quality of life. Individualised therapy can help patients return to work earlier, with all the associated benefits this will have for the gross national product. Drug therapies are associated with very high costs. Since 2004, the cost of drugs has been higher than the costs of medical treatment. One of the reasons for these higher costs is the prices of recently approved drugs, particularly in oncology. When it first came on the market tamoxifen cost $ 100 per month in the USA. However, prices for drugs are now significantly higher; nab-paclitaxel, for example, costs more than $ 7500 per month [10] . Moreover, as supportive therapies have improved and the management of side effects has got better, more patients now receive systemic therapies for longer periods of time. Currently, 15 billion USD are spent every year in the USA to treat breast cancer. The costs calculated for the year 2020 are expected to be just under 25 billion USD [10] . Studies generally consist of one cohort being given one form of therapy and the outcomes compared with those of another cohort which has either been treated using a different therapy or receive no therapy at all. The benefit of the therapy is then evaluated based on the increase in disease-free survival or overall survival. If the patient remains healthy, this could indicate that the treatment was effective and therefore the patient did not suffer a recurrence of disease. However, there is also the possibility that the patient would not, in any case, have suffered a recurrence and that her therapy therefore constituted a form of overtreatment (l " Fig. 1 ). This clearly shows the importance of identifying those women in advance who will respond to a particular therapy or who are likely to suffer from specific side effects. Tests which support a decision for or against a specific drug therapy can be expected to play increasingly important roles in future. The molecular classification of breast carcinomas into subtypes such as luminal A, luminal B, HER2-positive or basal-like is becoming more central for decision-making on treatment strategies [7, 17, 18, 27] . The existing data show that the classification of molecular subtypes is relevant for prognosis and that the decision on the choice of therapy can be made based on this classifi-Durchführung einer 10-jährigen Nachsorge bis zum Abschluss der Erkrankung befinden sich derzeit über eine halbe Million Frauen in Deutschland in der Betreuung. Zudem sind geschätzt 60 000 Frauen in der metastasierten Situation. In Bezug dazu lebten in Deutschland im Jahr 2010 32 cation. However, this type of molecular diagnostics is not yet comprehensively possible, and so currently available clinical or pathological characteristics are linked to subtypes (e.g. ER/PR positive, G1, low Ki-67 status, HER2/neu-negative for luminal A). Other possible tests include creating gene expression profiles from the tumour, gene copy variations, creating gene expression profiles of healthy stromal cells, epigenetic chips, miRNA chips, SNP chips and proteomics (e.g. PAI) and SNP chips to investigate germline DNA. The Oncotype DX ® , MammaPrint ® or Femtelle ® tests have a huge potential in this context, although we need to await the results of prospective trials for the former. Calculation programmes are also still very useful. While they are not molecular tests, they can be used to calculate the prognosis of a patient with or without treatment using clinical and pathological factors, and to support individual treatment decisions. Examples of such calculation programmes include Adjuvant! Online, PREDICT and PREDICT Plus [22, 29, 31] . l " Table 1 provides an overview of the options available to guide individualised treatment decisions. But the question quickly arises as to who should pay for these tests. At the moment, many tests are paid "out of pocket", i.e., affected patients in Germany pay for the tests themselves. The certified breast cancer centres in Germany are currently underfunded and barely capable of absorbing further costs [3, 4] . Health economic evaluations should be used to evaluate these tests and their impact on healthcare services. A cost-utility analysis can be used to assess the effects of a measure (in this case, the tests) and to weigh their importance [19] . The results of the costutility analyses can be used in international comparisons and in comparisons with other interventions and to support decisions by funding agencies whether to finance tests. Internationally, quality-adjusted life years (QALYs) are the most common measure used for such assessments; QALYs are a measure of the number of additional years obtained by an intervention, with one year lived in perfect health assigned the value of 1.0; the value is adjusted accordingly to reflect quality of life. No figures have been defined for Germany, as decisions on tests are made by the Federal Joint Committee (Gemeinsamer Bundesausschuss) after their assessment by the IQWiG (the Institute for Quality and Efficiency in Healthcare). In the USA, costs below $ 50 000 per QALY are considered cost-effective and costs over $ 100 000 as very high. In the latter case, approval is only given after a detailed clinical justification. When the costs of an intervention are between $ 50 000 and $ 100 000 a detailed assessment is made which in- 
Test
Treatment will be effective Treatment will not be effective Fig. 1 The importance of the early identification of patients who will respond or not respond to a specific therapy [33] .
cludes careful examination of the expected benefit. l " Table 2 shows examples of costs per QALY.
Tests for Primary Prevention
! Tests are used more commonly to plan therapy than many people are initially aware of. The classic example is testing for BRCA-1/2 mutation. With a cost of 5400 $ per QALY this is considered very cost-effective [10] . Prophylactic measures are taken if a mutation is identified. This helps save costs later on by preventing the development of primary breast cancer, recurrence or metastatic disease. Health economic evaluations of the benefits of this test are also available. Grann et al. [2] investigated the cost-effectiveness of intensified screening using mammography and/or MRT compared to prophylactic mastectomy and/or ovariectomy compared to chemotherapeutic prevention in a group of women with the mutation but without disease. Prophylactic ovariectomy in Table 1 Range of options used to make individualised treatment decisions for patients with breast cancer.
Relevance
Test method Material used for testing women with BRCA-1 mutation as the sole measure was associated with a cost of $ 1741 per QALY and thus predominated compared to the combination of both prophylactic operations and to all other options. For women with BRCA-2 mutation, prophylactic mastectomy was the most cost-effective measure ($ 5062/QALY).
Possible indication Recommendation
Overall, both types of prophylactic surgical interventions offered a better QALY compared to screening and chemotherapeutic prevention. It is therefore regrettable that these surgical interventions are currently not adequately reimbursed in Germany. For a subcutaneous mastectomy with subpectoral bilateral implantation of prostheses in a woman with BRCA-1 mutation (DRG J24B [2009]), the Gynaecological Hospital of the University Clinic of Erlangen receives € 4191.87 in total (cost-unit accounting) compared to the actual cost of the intervention of € 7097.17 (total: € − 2905.30). This DRG does not change even if a decision is taken to carry out bilateral synchronous adnexectomy to benefit the patient and avoid a second surgical intervention; the reimbursement remains the same, despite the higher costs incurred.
Diagnostic Tests
! Another example in routine clinical practice is the HER2/neu test to identify patients who will respond to anti-HER2 therapy (e.g. trastuzumab, lapatinib). Many people are not aware that even the smallest changes in the sensitivity and specificity of different diagnostic methods may represent immense costs for healthcare services. If a patient tests false-negative, she will not receive therapy; the treatment of recurrent cancer and/or metastasis due to the false-negative test will generate additional costs. If the patient tests false-positive, the cost-intensive treatment ($ 27 446 per adjuvant patient in the USA; approx. € 44 000 per adjuvant patient in Germany) generates additional unnecessary costs [16, 20] . A review of the literature was recently published which included an analysis of 46 studies [16] . Immunohistochemistry (IHC) was compared with tests such as fluorescence in situ hybridisation (FISH), chromogenic in situ hybridisation (CISH) and silver in situ hybridisation (SISH) and the respective sensitivities and specificities were compared. A total of 5 different scenarios were analysed (primary FISH, primary CISH, primary SISH, IHC with confirmation using FISH for 2+, IHC and confirmation using FISH for 2+ and 3+). The benefit obtained with trastuzumab therapy was assumed to be 1.18 QALYs. Even though the in situ hybridisation methods were initially significantly more expensive ($ 418 vs. $ 119 for IHC), the primary FISH test almost always performed better compared to a stepwise procedure using primary immunohistochemistry. None of the studies was able to show that IHC followed by FISH for 2+ was the most cost-effective option, although this combination is the current standard in Germany. All of the methods (IHC, FISH and CISH) have been approved for testing. As tests are usually done in the context of a DRG, costs which are used to justify the current standard do play an important role. In the longer term, it would be in the interests of funding agencies and healthcare services to provide adequate funding for the best test methods as this could significantly reduce follow-up costs. This is even more important when considering future developments such as pertuzumab and T-DM1 as well as potential dual anti-HER2 therapies. Tests for Supportive Therapy ! When evaluating predictive tests, it is also important to take account of tests which can be used to predict the specific side effects of therapies, as these can also involve high follow-up costs. Current studies have focussed on pharmacogenetic investigations which predict the rate of neutropenias occurring during chemotherapy or the occurrence of arthralgia during therapies with aromatase inhibitors. The DPYD*2A mutation, which is present in around 3 % of the Caucasian population, is of particular interest in this context. Therapy with 5-FU or capecitabine can result in extremely serious bone-marrow toxicity in this segment of the population or even be lethal. The investigation into the cost-effectiveness of genetic analysis for dihydropyrimidine dehydrogenase deficiency (enzyme for the metabolisation of fluoropyrimidine) was done by genotyping 1700 patients [8] . The heterozygote variant was found in 1 % of tested patients. Even though the costs of testing were initially high, the total costs were lower as follow-up costs could be avoided. By reducing the dosage, toxicity was reduced compared to the levels reported in the literature (toxicity ≥ level 3: 15 vs. 68%; mortality 10 vs. 0%).
Tests for Adjuvant Systemic Therapies
! Indications for adjuvant systemic therapy are currently predominantly based on node status, HER2/neu status, hormone receptor status, grading and age at onset of disease [15] . The indication should be made by an interdisciplinary tumour conference. The patientʼs wishes, expectations and co-morbidities need to be taken into account [15] . The recent focus has been on tests which can be used to plan systemic therapy for patients with breast cancer. The best known of these tests are the Oncotype DX ® , Femtelle ® and Mammaprint ® tests (l " Table 1 ). When assessing the costs and health economic impact of these tests it is important to take the current costs of decision-making as the starting point. Quality-assured immunohistochemical investigation currently plays the most important role in this assessment. As testing in certified breast cancer centres is done on an inpatient basis, the current costs based on the German medical fee schedule are as follows: " determination of oestrogen receptor expression: € 61.20 (4815 a × 3), " determination of progesterone receptor expression:
€ 61.20 (4815 a × 3), " determination of Ki-67 proliferation index:
€ 40.80 (4815 a × 2), " determination of HER2/neu status using immunohistochemisty: € 81.60 (4815 a × 4). cinoma-associated genes and 5 reference genes) is calculated [21] . The test has been retrospectively clinically validated using samples and results of the NSABP B-14 trial. The test provides an individualised prognosis for the risk of distant recurrence after 10 years for node-negative ER+ patients who receive adjuvant therapy for 5 years with tamoxifen (NSABP B14) and an individualised prediction of the benefit of tamoxifen (NSABP B-14) and of chemotherapy for node-negative HR+ patients . It can also be used to calculate the individualised prognosis and estimate the benefit of chemotherapy for node-positive HR+ patients based on the ECOG 2197 and SWOG 8814 trials [1] . If the costs of testing are taken into consideration, the question is whether this approach will save costs or generate additional costs. [12] .
Their study looked at a cohort of node-positive and hormone receptor-positive patients in the UK. Average patient age was around 60 years and DFS data were based on the SWOG 8814 trial. The model also took anthracycline-induced cardiomyopathy after chemotherapy into account. All costs were based on the NICE guidelines and the NHS reference costs for 2011. The results are shown in l " Table 3 . The authors also calculated the potential impact on the UK healthcare system. With the cost of chemotherapy per patient calculated as £ 6243, a total of £ 49 000 000 was spent annually in the UK without using the Oncotype DX ® test. When costs were calculated based on the assumption that 70 % of chemotherapies could be avoided with the Oncotype DX ® test, it was found that savings of £ 35 000 000 could be generated annually. With a test cost of £ 2576 per patient, the total annual cost of testing would be £ 20 000 000. This would result in a total saving of £ 14 000 000 per year in the UK. These results must be qualified, however, by noting that the rate of avoidable chemotherapies may be too high (the rates reported in the literature are between 11.9 and 70.6 %), that no other tests were included in the calculation, that Adjuvant! Online (which is available free of charge) was not included either, and that the average patient age was given as 60 yearsyounger patients benefit significantly more from chemotherapy. This prompts the question what impact testing would have on cost-effectiveness and on the German healthcare system. The impact on costs in Germany was recently calculated [5] . [26] . Before recommending general use of these tests, the commission wants to wait for the results of prospective trials such as TAILOR-X and MINDACT. The current interdisciplinary S3 Guidelines for the diagnosis, treatment and follow-up of breast cancer has also commented on the test methods [15] . According to the S3 Guidelines, the Oncotype DX ® test should be used where appropriate to assess the benefit of chemotherapy when conventional markers do not permit a clear classification of risk. Use of the test is therefore only recommended on an individual basis. As regards the MammaPrint ® test, which was licensed for use as a prognostic test in 2007 by the U S Food and Drug Administration (FDA), it must be emphasised that no guidelines currently recommend the use of this test. It should also be noted that none of the existing guidelines include a systematic review of the literature on gene expression tests. It is not possible to rule out potential injury to patients (recurrence and metastatic disease which could have been prevented by chemotherapy). The evidence is therefore still insufficient to accurately assess the ratio between benefits and risks when using such tests. Further studies will be necessary to close the important gaps in our knowledge.
Testing for the biomarkers uPA and PAI can be done to avoid unnecessary chemotherapy in patients with primary breast cancer classified as medium risk (G2, N−, HR+, HER2/neu−, > 35 years). A prospective, multi-centre study found that use of these biomarkers in 93 patients prevented 35 chemotherapies or 12.1 years of chemotherapy application (calculation based on 210 cycles) [14] . Costs of € 221 816 for systemic therapy, € 25 749 for GCS-F and $ 34 353 for additional supportive therapies were saved (total savings: $ 281 918). With test costs of $ 350 per patient, the return-of-investment ratio was 8.4 : 1 (l " Table 3 ). The costs of side-effects, of short and long-term chemotherapyrelated morbidities and the cost savings achieved by avoiding inpatient stays and febrile neutropenia were not included, nor were absences from work due to effect of chemotherapy and the costs of the burden on the family; all of these would significantly increase the ratio in favour of testing. However, in this era of gene expression profiles, it should not be forgotten that web-based prognostic tools are also available to calculate the prognosis and estimate the benefits of systemic therapy (l " Table 1 ). The web-based programme Adjuvant! Online was introduced in 2001 and offers a model to calculate patient prognosis [22] . The benefit of endocrine therapy compared to chemotherapy or a combination of both was calculated using data obtained from the Early Breast Cancer Trialists Collaborative Group und the Surveillance Epidemiology and End Results Program (SEER). The model was validated in several case-control studies. The PREDICT prognostic model, an online tool which calculates prognosis and estimates the benefit of treatment, was developed in the UK, based on data from 5694 breast cancer pa- tients for the years 1999 to 2003 [29] . The model has been validated in various independent cohorts and compared with the Adjuvant! model. Both models accurately calculated overall survival and breast cancer-specific survival [30] . However neither of the models included HER2/neu status in their calculations and therefore also ignored the potential benefit of HER2-targeted therapy. The prognostic effect of HER2/neu status was subsequently determined and included in the PREDICT model, using the data of 10 179 patients with breast cancer from 14 trials of the Breast Cancer Association Consortium (BCAC). This PREDICT Plus model was validated using the data of 1613 patients with early-stage breast cancer [31] . All 3 calculation programmes were found to be reliable, although PREDICT Plus was much better at predicting overall survival and breast cancer-associated survival of HER2/neu-positive patients. As these prognostic tools are available free of charge, use of these programmes could be extremely cost-effective. However, as yet only a limited number of health economic evaluations of these programmes are available ( Clearly patients need to be better informed. They require sufficient basic information to allow them to make a decision for or against a specific test [28] . The benefits and disadvantages of the respective tests must be described and weighed up together with the patient. The existing recommendations in the S3 Guidelines should be presented [15] . For this it would be necessary that attending physicians look at the data on tests and consider the uses of these tests. The assessment of tests from a health economic standpoint offers an additional criterion for their evaluation and makes it easier to assess the respective benefits compared to other prognostic methods. In addition, it is not reasonable to expect that patients will continue to pay for tests for individualised treatment in future, particularly if it can be clearly shown that these tests optimise treatment and help funding agencies reduce the costs born by the community. Funding agencies must accept individual therapy decisions. It would be useful if funding agencies would support further research and more detailed studies on this topic.
Conclusion

!
Genetic and molecular tests are initially associated with higher costs. In the longer term, however, costs can be reduced by using these new tests to avoid unnecessary treatment, to improve the effectiveness of systemic therapies by identifying those patients who will benefit, and to optimise the management of side-effects. The reduction in costs achieved with these new tests will affect health economics and ultimately have an impact on health policies. But funding agencies have yet to realise the benefits of these new methods and provide sufficient funding of these test methods. 
